Skip to main content
. Author manuscript; available in PMC: 2019 Apr 6.
Published in final edited form as: Biochem Biophys Res Commun. 2018 Mar 6;498(3):573–578. doi: 10.1016/j.bbrc.2018.03.021

Figure 4. Survivin contributes to EMT by activating TGFβ pathways.

Figure 4

A. Western blot analysis of survivin expression following different doses of TGFβ treatment for 24 h (**p<0.01;***p<0.001). B. Western blot analysis of survivin (*p<0.05) and phospho-SMAD2 (***p<0.001) expression following 20 µM TGFβ inhibitor and 6 ng/ml TGFβ treatment. C. Western blot analysis of phospho-SMAD2 (*p<0.05;**p<0.01) and total SMAD2/3 at different time points in survivin KD and control cells following 6 ng/ml TGFβ treatment. D. Western blot analysis of phospho-SMAD2 (**p<0.01) and total SMAD2/3 in wildtype ARPE-19 cells following 20 nM YM155 treatment for 4 h, then treated with 6 ng/ml TGFβ. E. Survivin KD and control cell morphology following 6 ng/ml TGFβ treatment for 24 h. F. Wildtype ARPE-19 cell morphology at 24 h following 20 nM YM155 treatment and then with 6 ng/ml TGFβ treatment.